MX2022000373A - Combinacion de ibuprofeno y tramadol para aliviar el dolor. - Google Patents

Combinacion de ibuprofeno y tramadol para aliviar el dolor.

Info

Publication number
MX2022000373A
MX2022000373A MX2022000373A MX2022000373A MX2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A
Authority
MX
Mexico
Prior art keywords
tramadol
combination
ibuprofen
relieve pain
pain
Prior art date
Application number
MX2022000373A
Other languages
English (en)
Spanish (es)
Inventor
Calvo Antonia Gómez
Menéndez Nuria Sanz
De La Torre Marta Vicario
Alonso Fernando García
Pérez Antonio Portolés
Serna Luis Narciso Santé
Butrón María Del Rosario Salas
Castrillón Emilio Vargas
Pérez Carlos Calandria
Córdoba Raquel Horcajada
Ruiz Ángel José Muñoz
García Jose Angel Sánchez
Gonzalez Ester Duart
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of MX2022000373A publication Critical patent/MX2022000373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2022000373A 2019-07-09 2020-07-08 Combinacion de ibuprofeno y tramadol para aliviar el dolor. MX2022000373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382583 2019-07-09
PCT/EP2020/069306 WO2021005129A1 (en) 2019-07-09 2020-07-08 Combination of ibuprofen and tramadol for relieving pain

Publications (1)

Publication Number Publication Date
MX2022000373A true MX2022000373A (es) 2022-02-10

Family

ID=67480112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000373A MX2022000373A (es) 2019-07-09 2020-07-08 Combinacion de ibuprofeno y tramadol para aliviar el dolor.

Country Status (21)

Country Link
US (1) US12514833B2 (cg-RX-API-DMAC7.html)
EP (1) EP3996699B1 (cg-RX-API-DMAC7.html)
JP (1) JP7656339B2 (cg-RX-API-DMAC7.html)
CN (1) CN114080221B (cg-RX-API-DMAC7.html)
AU (1) AU2020309160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145632C (cg-RX-API-DMAC7.html)
DK (1) DK3996699T3 (cg-RX-API-DMAC7.html)
ES (1) ES2952013T3 (cg-RX-API-DMAC7.html)
FI (1) FI3996699T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230677T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062529T2 (cg-RX-API-DMAC7.html)
MA (1) MA56341B1 (cg-RX-API-DMAC7.html)
MD (1) MD3996699T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000373A (cg-RX-API-DMAC7.html)
MY (1) MY207573A (cg-RX-API-DMAC7.html)
PL (1) PL3996699T3 (cg-RX-API-DMAC7.html)
PT (1) PT3996699T (cg-RX-API-DMAC7.html)
RS (1) RS64500B1 (cg-RX-API-DMAC7.html)
SI (1) SI3996699T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021005129A1 (cg-RX-API-DMAC7.html)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
IT1264857B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
WO2000025769A1 (en) 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US6211246B1 (en) 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6342530B1 (en) 2000-11-14 2002-01-29 Farmacon-Il, Llc Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
US6727286B2 (en) 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
JP5185488B2 (ja) 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ,インコーポレーテッド 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物
EP1558234B1 (en) 2002-10-25 2007-05-23 Dompé S.P.A. Painless injectable compositions containing salt of 2-arylpropionic acids
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
EP2149546A1 (en) * 2008-07-31 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Salts of tramadol and ibuprofen and their crystal form in the treatment of pain
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
AU2010224063B2 (en) 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
ES2356762B1 (es) * 2009-09-04 2011-11-24 Farmalider S.A. Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma.
MX2010004974A (es) 2010-05-04 2011-11-23 Senosiain S A De C V Lab Combinacion de un aine y un aminoacido.
US8895622B2 (en) 2011-04-12 2014-11-25 Revogenex Ireland Ltd. Intravenous administration of tramadol
PT2636406E (pt) 2012-02-20 2015-11-20 Pharmaceutical Solutions Industry Ltd Perfusão intravenosa de ibuprofeno
ES2423866B1 (es) * 2012-02-22 2014-06-10 Farmalider, S.A. Composición farmaceútica de ibuprofeno y tramadol para inyección
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
CN106413717A (zh) * 2014-04-10 2017-02-15 查尔斯顿实验室公司 药物组合物

Also Published As

Publication number Publication date
HUE062529T2 (hu) 2023-11-28
US12514833B2 (en) 2026-01-06
AU2020309160B2 (en) 2025-06-26
CA3145632C (en) 2024-03-12
MY207573A (en) 2025-03-05
BR112022000242A2 (pt) 2022-05-31
JP2022540854A (ja) 2022-09-20
JP7656339B2 (ja) 2025-04-03
HRP20230677T1 (hr) 2023-10-13
ES2952013T3 (es) 2023-10-26
FI3996699T3 (fi) 2023-08-01
RS64500B1 (sr) 2023-09-29
EP3996699B1 (en) 2023-06-28
AU2020309160A1 (en) 2022-02-17
PT3996699T (pt) 2023-07-27
MD3996699T2 (ro) 2023-11-30
DK3996699T3 (da) 2023-07-24
CA3145632A1 (en) 2021-01-14
US20220249414A1 (en) 2022-08-11
CN114080221A (zh) 2022-02-22
WO2021005129A1 (en) 2021-01-14
MA56341B1 (fr) 2023-07-31
SI3996699T1 (sl) 2023-10-30
CN114080221B (zh) 2023-12-05
PL3996699T3 (pl) 2023-10-30
EP3996699A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
PE20242299A1 (es) Composiciones agonistas de gip/glp1
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2019012884A (es) Terapia de combinacion.
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR113906A1 (es) Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
MX2024011932A (es) Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno